Home Contact

logo

Family

Links:






Archives:


Newsletter:

Register for our Free monthly newsletter to receive timely updated information about Parkinsons Disease directly in your email.
Email
First Name
Last Name
Zip Code

Categories:



Register for our FREE monthly newsletter to receive timely updated information about Parkinsons Disease directly in your email.

Archive for June, 2008

Myoclonus can be confused with Parkinson’s

Friday, June 27th, 2008

Hand Tremor I recently learned of a fellow blogger whose blog I read often was diagnosed with Parkinson’s but after a few rising symptoms that weren’t assimilated with Parkinson’s disease the doctors she visited took back their diagnosis and then diagnoses her with essential myclonus. For months she has had Parkinson’s like symptoms as well as some other symptoms and to treat these symptoms she has been on multiple drugs for Parkinson’s disease. For quite a while she suffered and had a very difficult time coping with her mis-diagnosis and the psychology of not knowing what plagued her. So here is a basic run-down of myoclonus.

First, myoclonus has different forms, essential myoclonus is one form of myoclonus. The causes of myoclonus is unclear, there are still many unknowns. From what researchers have gathered it is a failing of the nervous system, usually this happens in the area of the brain called the cortex–the outer layer of your brain that is heavily involved in information processing, including skilled and voluntary movement. Many think that an imbalance of brain chemicals causing the nervous system to struggle.

There are a few different kinds of Myoclonus:

Physiological Myoclonus

This type can occur in normal, healthy people. Examples include sleep starts (when you jerk in your sleep) this often happens just before one falls asleep. Hiccups are another example. Hiccups are an involuntary movement of the diaphram.

Essential Myoclonus

Essential myoclonus occurs on its own. The most prominent symptom is the muscle jerks. This type isn’t progressive as well, which for my friend was great news! Some researchers believe that cause is idiopathic (meaning it is caused by an unknown or peculiar reason), other researchers believe it’s hereditary.

Epileptic Myoclonus

This type of myoclonus is usually hooked to chronic seizures (like epilepsy). The jerks from the seizures may be a component of epileptic myoclonus.

Symptomatic Myoclonus

This is the most common form of myonoclus it occurs as a result of an underlying medical problem. Examples of problems that may cause myonoclus are:

  • Disease of the brian or nervous system
  • Infections
  • Metabolic disorders
  • Damage to the brain or nervous system
  • Disorders that affect your ability to digest nutrients

Opsoclonus-mynoclonus Syndrome

This type is characterized by rapid, irregular eye movements. It’s most often assocation with tumors in children. Treatment of the tumor may improve the symptoms of opsoclonus-myoclonus.

Palatal Myoclonus

Palatal myoclonus is characterized by rhythmic contractions of the muscles in the roof of the mouth. These contractions may cause a clicking sound in your ear. There may also be contractions in the face, tongue, throat and diaphragm muscles.

So that is a basic run-down of myoclonus, I’ve kept it as basic as possible, so if you have any specific questions that my post didn’t answer please let me know and I’ll do my best in answering them. I felt that this post was important because I know of people that get the wrong diagnosis all the time, so it’s important to keep these different conditions in mind.

To learn more about the trials that my fellow-blogger experienced feel free to visit her site. Her documentation will bless the lives of many, many people for years to come.

Wasington Post Reports: New Hope for Parkinson’s Patients

Wednesday, June 25th, 2008

TUESDAY, June 24 (HealthDay News) — A new medication and an improved delivery system for an older drug appear to hold promise for taming the symptoms of Parkinson’s disease.

In the first study, patients taking the drug SLV308 showed significant reductions in typical Parkinson’s symptoms, such as tremors and slowness of movement. The results also indicate that SLV308 alone may help patients in the early stages of Parkinson’s disease.

Patients appeared to tolerate SLV308 well, although it did cause side effects such as nausea, dizziness, drowsiness, headache and weakness. The study was supported by the drug’s maker, Solvay Pharmaceuticals.

In the second study, a patch delivery system for levodopa also appeared to ease motor problems in Parkinson’s patients.

The study compared healthy volunteers on a levodopa patch against those taking carbidopa orally every eight hours over a 24-hour period. Those with the patch appeared to receive a more constant therapeutic delivery of medication.

“If levodopa can be administered in a way to bypass the gastrointestinal tract, which is responsible for the vagaries which complicate levodopa dosing in [Parkinson's] patients now, it would be an important step forward,” Dr. John Nutt, of Oregon Health & Science University, said in a prepared statement. “Transdermal administration would produce more constant plasma levels than can be achieved with oral dosing, which should reduce motor fluctuations and possibly, dyskinesia.”

The results of the studies were presented this week at the Movement Disorder Society’s 12th International Congress of Parkinson’s Disease and Movement, in Chicago.

Fishing out Parkinson’s

Wednesday, June 25th, 2008

I am definitely a fan of fish especially as of late, so the news article I read about how fish can potentially protect people from Parkinson’s disease was great news.  Now, for those of my readers that have Parkinson’s disease you may be saying…”what’s Caleb thinking, I already have Parkinson’s,” but this may be important information to pass down to your relatives.  From my readings I think there needs to be more research into this, but just eating more fish is healthier then red meat (at least for the most part), so in the end implementing more fish into your diet is not a bad idea at all.

Laval University in Canada fed mice a diet high in omega-3 fatty acids and they found that the mice they fed omega-3 fatty acids did not develop Parkinson’s even when they were given a toxic compound that usually causes symptoms of Parkinson’s.

In an article that discusses this matter:

“The mice were fed very high doses of the omega-3 acid known as DHA, which is not the same as the omega-3s contained in some vegetable oils. What’s more, the researchers were unable to say how much of DHA humans should consume to achieve the same protection against Alzheimer’s.

However, two servings of fish a week would probably help, said Frederic Calon, co-author of the study.”

Two servings, that’s it… one night at Red Lobster a week may just be a huge help to your family.  Like I said this study (and other studies that are similar) need to be flushed out

Old Muscle Given New Pep By Stem Cell Researchers

Tuesday, June 24th, 2008

Old muscle got a shot of youthful vigor in a stem cell experiment by bioengineers at the University of California, Berkeley, setting the path for research on new treatments for age-related degenerative conditions such as muscle atrophy or Alzheimer’s and Parkinson’s diseases.

In a new study published in an advanced online issue of the journal Nature, researchers identified two key regulatory pathways that control how well adult stem cells repair and replace damaged tissue. They then tweaked how those stem cells reacted to those biochemical signals to revive the ability of muscle tissue in old mice to repair itself nearly as well as the muscle in the mice’s much younger counterparts.

Irina Conboy, an assistant professor of bioengineering and an investigator at the Berkeley Stem Cell Center and at the California Institute for Quantitative Biosciences (QB3), led the research team conducting this study.

Because the findings relate to adult stem cells that reside in existing tissue, this approach to rejuvenating degenerating muscle eliminates the ethical and medical complications associated with transplanting tissues grown from embryonic stem cells.

“We are one step closer to having a point of intervention where we can rejuvenate the body’s own stem cells so we don’t have to suffer from some of the debilitating diseases associated with aging,” said the study’s lead author, Morgan Carlson, a recent Ph.D. graduate of Conboy’s lab.

The researchers focused on the interplay of two competing molecular pathways that control the stem cells, which sit next to the mature, differentiated cells that make up our working body parts. When the mature cells are damaged or wear out, the stem cells are called into action to begin the process of rebuilding.

“We don’t realize it, but as we grow our bodies are constantly being remodeled,” said Conboy. “We are constantly falling apart, but we don’t notice it much when we’re young because we’re always being restored. As we age, our stem cells are prevented, through chemical signals, from doing their jobs.”

The good news, the researchers said, is that the stem cells in old tissue are still ready and able to perform their regenerative function if they receive the appropriate chemical signals. Studies have shown that when old tissue is placed in an environment of young blood, the stem cells behave as if they are young again.

“Conversely, we have found in a study published last year that even young stem cells rapidly age when placed among blood and tissue from old mice,” said Carlson, who will stay on at UC Berkeley to expand his work on stem cell engineering either as a QB3 fellow or a postdoctoral researcher. He will be supervised by Conboy; Tom Alber, professor of biochemistry; and David Schaffer, associate director of the Berkeley Stem Cell Center and professor of chemical engineering.

Adult stem cells have a receptor called Notch that, when activated, tells them that it is time to grow and divide, the researchers said. But stem cells also have a receptor for the protein TGF-beta that sets off a chain reaction activating the molecule pSmad3 and ultimately producing cyclin-dependent kinase (CDK) inhibitors, which regulate the cell’s ability to divide.

“Interestingly, activated Notch competes with activated pSmad3 for binding to the regulatory regions of the same CDK inhibitors in the stem cell,” said Conboy. “We found that Notch is capable of physically kicking off pSmad3 from the promoters for the CDK inhibitors within the stem cell’s nucleus, which tells us that a precise manipulation of the balance of these pathways would allow the ability to control stem cell responses.”

Notch and TGF-beta are well known in molecular biology, but Conboy’s lab is the first to connect them to the process of aging, and the first to show that they act in opposition to each other within the nucleus of the adult stem cell.

Aging and the inevitable march towards death are, in part, due to the progressive decline of Notch and the increased levels of TGF-beta , producing a one-two punch to the stem cell’s capacity to effectively rebuild the body, the researchers said.

“What we discovered is the interplay between two pathways – one an aging pathway, and the other a youthful pathway,” said Conboy.

But what would happen if researchers blocked the adult stem cells in old tissues from reacting to those TGF-beta signals? The researchers put that question to the test in a living organism by comparing the muscle regeneration capacity of old, 2-year-old mice, comparable in age to a 75- to 80-year-old human, with that of 2-month-old mice, similar in age to a 20- to 25-year-old human.

For a group of the old mice, the researchers disabled the “aging pathway” that tells stem cells to stop dividing by using an established method of RNA interference that reduced levels of pSmad3. The researchers then examined the muscle of the different groups of mice one to five days after injury to compare how well the tissue repaired itself.

As expected, the researchers found that muscle tissue in the young mice easily replaced damaged cells with new, healthy cells. In contrast, the areas of damaged muscle in the control group of old mice were characterized by fibroblasts and scar tissue.

However, muscles in the old mice whose stem cell “aging pathway” had been dampened showed levels of cellular regeneration that were comparable to their much younger peers, and that were 3 to 4 times greater than those of the group of “untreated” old mice.

The researchers cautioned that shutting down the TGF-beta/pSmad3 pathway altogether by turning off the gene that controls it could lead to many health problems. The ability to suppress cell division is critical in controlling the development of tumors, for instance.

“When we are young, there is an optimal balance between Notch and TGF-beta,” said Conboy. “We need to find out what the levels of these chemicals are in the young so we can calibrate the system when we’re older. If we can do that, we could rejuvenate tissue repair for a very long time.”

The researchers also warn against interpreting this research as the cure-all for aging.

“We’re not at a point where we’re ready to inject ourselves with TGF-beta antibodies and call it a day,” said Carlson. “There are multiple mechanisms involved in how our body functions. We know that TGF-beta is involved in one aspect of aging, but we don’t know where it fits in the global scheme of aging.”

In addition to their work on adult stem cells, Carlson and Conboy have also discovered that human embryonic stem cells can actually neutralize the effects of aging. Conboy received funding last year from the California Institute for Regenerative Medicine (CIRM) to pursue this line of research.

Parkinson`s Drug Market

Friday, June 20th, 2008

Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the generic erosion of market leading therapies will constrain the Parkinson’s disease drug market, resulting in an annual market growth rate of only 1.4 percent through 2017 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

The new Pharmacor report entitled Parkinson’s Disease finds that the generic erosion of Boehringer Ingelheim’s Mirapex/Mirapexin/Sifrol, GlaxoSmithKline’s Requip, Teva/Lundbeck’s Agilect/Azilect and Novartis/Orion’s Stalevo will cause sales of these agents to decline over the next decade, despite their increased use. The key agents in the dopamine agonist drug class, Requip and Mirapex/Mirapexin/Sifrol, will be most significantly affected by near-term generic erosion through 2012.

The modest growth of the Parkinson’s disease drug market over the next decade will be driven by the arrival of once-daily formulations of current market leading dopamine agonists, GlaxoSmithKline/SkyePharma’s Requip XL/CR/LP and Boehringer Ingelheim’s pramipexole ER. Growth will also be driven by the launch of two new therapies-Merck Serono/Newron’s safinamide and Solvay’s pardoprunox-and by increases in drug-treatment rates due to aging populations in the world’s major pharmaceutical markets.

“The greatest unmet need in Parkinson’s disease treatment, the need for a disease-modifying therapy, will remain unfulfilled over the next 10 years,” said Sami Fam, Ph.D., analyst at Decision Resources. “Key opinion leaders in this therapeutic area unanimously agree that the most critical need is for drugs that can act on the pathological mechanisms of Parkinson’s disease and provide neuroprotection and/or neurorestoration. Critical to addressing this unmet need will be a better understanding of the cellular mechanisms that underlie the pathology of Parkinson’s disease.”

http://www.rehabpub.com/press_release.asp?id=10203258

Dr. Peter Gott`s take on Q10

Thursday, June 19th, 2008

I just read this article, I plan to do some more research and cover Q10 for my readers, I plan to do that when I get home from El Salvador on Monday, until then Dr. Peter Gott`s take will have to do.  Please email me if you have any insight/opinion of Q10 at caleb@imedmarkets.com.

By PETER GOTT

Dear Dr. Gott: I was diagnosed with Parkinson’s disease in June 2005. I take Mirapex, which is prescribed, and co-enzyme Q10, which is not. I read somewhere that Q10 is a good over-the-counter for people with Parkinson’s disease. Could you please comment on this?

Dear Reader: Parkinson’s is a neurological disorder that results from the loss of brain cells that produce dopamine, a chemical substance that transmits nerve impulses. Dopamine is essential for normal functioning of the central nervous system. When the neurons that produce dopamine die, that part of the brain responsible for coordinating movement malfunctions and leads to tremor, rigidity, lack of coordination, sleep disturbances, difficulties with movement and more.

Recent studies performed on mice have been promising, revealing that the damaged area of the brain in Parkinson’s patients can be protected by slowing the progression of the disease with the use of co-enzyme Q10. It should be noted, however, that larger studies and double-blind studies on humans must be coordinated to determine the validity of such results.

From what I can determine, this product is effective in lowering cholesterol levels and also appears effective in slowing the progress of symptoms. Speak with your neurologist regarding his views and recommendations for this supplement.

This is a good time for me to clarify something I said in a past column regarding Parkinson’s disease. When discussing advancement of the disease, I indicated that some people are blessed with a complete cure within months. What I should have said was that some people go into remission without advance of symptoms, giving the appearance of a complete cure.

Write Dr. Gott c/o United Media, 200 Madison Ave. 4th floor, New York, NY 10016.

Originally published by PETER GOTT Newspaper Enterprise Association.

(c) 2008 Tulsa World. Provided by ProQuest Information and Learning. All rights Reserved.

 

Source: Tulsa World

Requip XL and SkyePharma

Thursday, June 19th, 2008

SkyePharma Plc (SKP.L: News, Chart, Quote , SKYEF.PK, SKYEY.PK) said Monday that the U.S. Food and Drug Administration or FDA has approved Requip XL, a drug developed by GlaxoSmithKline Plc’s (GSK, GSK.L) for the treatment of Parkinson’s disease. SkyePharma would receive low-mid single digit royalties on sales of the product, which is expected to hit the U.S. market in mid-July 2008.

The London, U.K.-based SkyePharma noted that Requip XL or ropinirole extended-release tablets, currently approved in 23 countries in Europe, are the first and only once-daily, oral, non-ergot dopamine agonist indicated for the disease. The new formulation uses its patented Geomatrix technology, a tri-layer formulation, which allows a 24-hours continuous delivery of the medicine to provide smooth blood levels.

SkyePharma stated that the FDA approval was based principally on results from an Efficacy And Safety Evaluation in Parkinson Disease Adjunct Study. The multi-center, double blind, placebo-controlled study was conducted in 393 patients with idiopathic Parkinson’s disease not adequately controlled with L-dopa. The study’s primary endpoint was the mean change from baseline at week 24 in awake time spent “off,” which was measured via patient diaries.

The results demonstrated that extended-release ropinirole significantly reduced “off” time by an average of 2.1 hours per day from baseline, compared with a reduction of 0.4 hours per day for placebo. The study also showed that the once-daily use of ropinirole was generally well tolerated, and that the withdrawal rate due to adverse reactions was low and similar between groups.

SKP.L is currently trading on the LSE at 6.1120 pence, up 0.6120 pence, or 11.13%, on a volume of 749,076 shares.

GSK.L is trading currently on LSE at 1.088.80 pence, rising 13.00 pence, or 1.21%, with a volume of 1.9 million shares.

GSK closed trading on Friday at $42.04, up $0.44, or 1.06%, with a volume of 1.34 million shares.

SKYEY.PK closed Friday’s trading at $1.00, down $0.01, or 0.99%.

by RTT Staff Writer

http://www.rttnews.com/ArticleView.aspx?Id=631220&SMap=1